Respiratory medicine · 2026
Post-bronchodilator FEF25-75 and COPD exacerbations: The role of airflow obstruction severity in the KOCOSS cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Joo Hyonsoo, Park Shinhee, Jang Jong Geol, Lee Hyun, Rhee Chin Kook, Choi Cheon Woong, Hwang Yong Il, Yoo Kwang Ha, Kim Youlim, Moon Ji-Yong
Аннотация
BACKGROUND: FEF25-75 is a spirometric index of mid-expiratory flow that is strongly related to conventional airflow obstruction. We evaluated its association with 3-year COPD exacerbations and whether this association was independent of airflow obstruction severity.
METHODS: We analyzed 830 KOCOSS participants (≥40 years; post-BD FEV1/FVC <0.7; ≥10 pack-years) with post-bronchodilator FEF25-75 and complete 3-year exacerbation outcomes. Participants were categorized into quartiles of post-bronchodilator FEF25-75% predicted: Q1, ≥37%; Q2, 26-36%; Q3, 18-25%; and Q4, ≤17%. Logistic regression assessed the risk of at least one moderate-to-severe exacerbation, and negative binomial regression assessed cumulative exacerbation counts. Sequential models adjusted for clinical factors, FVC % predicted, and FEV1% predicted.
RESULTS: The proportion of participants experiencing at least one moderate-to-severe exacerbation increased from 54.0% in Q1 to 81.1% in Q4 (P < 0.001), and the mean cumulative exacerbation count increased from 2.0 to 5.8. In the clinical model, Q4 was associated with a higher risk of exacerbation (OR 2.67, 95% CI 1.66-4.30) and a higher cumulative exacerbation rate (IRR 2.32, 95% CI 1.68-3.19) compared with Q1. These associations persisted after adjustment for FVC, but were no longer significant after adjustment for FEV1 (OR 1.00, 95% CI 0.47-2.11; IRR 1.24, 95% CI 0.75-2.04).
CONCLUSIONS: Lower post-bronchodilator FEF25-75 identifies COPD patients with a higher long-term exacerbation burden; however, this association is predominantly attributable to FEV1-defined airflow obstruction severity. FEF25-75 should therefore be interpreted primarily as a marker of overall physiological impairment rather than an independent, small-airway-specific predictor of exacerbations.
METHODS: We analyzed 830 KOCOSS participants (≥40 years; post-BD FEV1/FVC <0.7; ≥10 pack-years) with post-bronchodilator FEF25-75 and complete 3-year exacerbation outcomes. Participants were categorized into quartiles of post-bronchodilator FEF25-75% predicted: Q1, ≥37%; Q2, 26-36%; Q3, 18-25%; and Q4, ≤17%. Logistic regression assessed the risk of at least one moderate-to-severe exacerbation, and negative binomial regression assessed cumulative exacerbation counts. Sequential models adjusted for clinical factors, FVC % predicted, and FEV1% predicted.
RESULTS: The proportion of participants experiencing at least one moderate-to-severe exacerbation increased from 54.0% in Q1 to 81.1% in Q4 (P < 0.001), and the mean cumulative exacerbation count increased from 2.0 to 5.8. In the clinical model, Q4 was associated with a higher risk of exacerbation (OR 2.67, 95% CI 1.66-4.30) and a higher cumulative exacerbation rate (IRR 2.32, 95% CI 1.68-3.19) compared with Q1. These associations persisted after adjustment for FVC, but were no longer significant after adjustment for FEV1 (OR 1.00, 95% CI 0.47-2.11; IRR 1.24, 95% CI 0.75-2.04).
CONCLUSIONS: Lower post-bronchodilator FEF25-75 identifies COPD patients with a higher long-term exacerbation burden; however, this association is predominantly attributable to FEV1-defined airflow obstruction severity. FEF25-75 should therefore be interpreted primarily as a marker of overall physiological impairment rather than an independent, small-airway-specific predictor of exacerbations.